Objective Study about the therapy effects on breast cancer in nude mice by UTMD with NMB, CMB and CMB105 carrying ES plasmid. Methods For inoculation, MDA-MB-231 tumor cell suspensions were injected subcutaneously in both hind limbs of nude mice. Xenograft tumors were allowed to grow for 14 days before the experimental studies began, NMB, CMB and CMB105 were injected into the tail vein, and 10 min after injection, ultrasound-mediated gene transfer was performed. Ultrasound was applied at 1 MHz, 2 W/cm2, and 50% duty cycle (DC) for 30 seconds, tumor xenografts on the left hind limb received the ultrasound mediated gene therapy and the right hind limb tumor xenografts were used as control. The size of tumor xenografts was recorded every 3 days. Fifteen days after transfer, the mice were sacrificed, the tumor growth inhibition rate was calculated and the tumor growth curve was delineated. qPCR and Western-blot were used to evaluate the level of ES mRNA and protein. Results UTMD-mediated endostatin gene delivery both with CMB and CMB105 significantly inhibited tumor growth, The inhibition rate of the CMB105 group was highest (53.18±5.69%) compared with CMB (27.57±3.02%) and NMB (10.63±1.47%). UTMD-mediated endostatin gene delivery with CMB105 could inhibit the tumor growth successfully. The level of ES mRNA and protein were increased both in CMB and CMB105 therapy group, and the difference between then was significant (P＜0.01). Conclusions UTMD-mediated ES gene delivery with CMB105 could inhibit the tumor growth successfully, the therapy effects were better than with CMB and NMB.